Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19014505 | 0.79 | — | — | |
| SCHEMBL22959616 | 0.78 | KDM4E (0.33) | HSD11B1KDM4EALDH1A1ALOX15JAK1 | |
| SCHEMBL7848036 | 0.78 | KDM4E (0.33) | KDM4EALDH1A1ALOX15JAK1SMYD3 | |
| SCHEMBL12439857 | 0.77 | ACHE (0.43) | HSD11B1KDM4EALDH1A1JAK1SMYD3 | |
| SCHEMBL20012520 | 0.77 | ACHE (0.43) | HSD11B1KDM4EALDH1A1JAK1SMYD3 | |
| SCHEMBL19013850 | 0.76 | HSD11B1 (0.34) | HSD11B1SMYD3 | |
| SCHEMBL615681 | 0.74 | KDM4E (0.35) | KDM4EALDH1A1ALOX15JAK1POLB | |
| SCHEMBL19013852 | 0.74 | JAK2 (0.38) | HSD11B1JAK1SMYD3 | |
| SCHEMBL19013698 | 0.74 | POLB (0.51) | ALDH1A1POLB | |
| SCHEMBL19014508 | 0.74 | JAK1 (0.41) | HSD11B1JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998958-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2011-08-16 | — | — | US | disclosed |
| US-7763613-B2 | Substituted N-arylsulfonylheterocyclic amines as gamma-secretase inhibitors | SCHERING CORPORATION (US) | 2010-07-27 | — | — | US | disclosed |
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | SCHERING CORP. | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093695-A1 | Substituted N-Arylsulfonylheterocyclic Amines As Gamma-Secretase Inhibitors | BACE1, BACE2, APP | HSD11B1 781/4885KDM4E 2481/4885ALDH1A1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.